Heart Valve Repair in India and UAE | Complete Patient Guide

• ELIGIBLE CANDIDATES:

• Patients with severe symptomatic degenerative mitral regurgitation (Stage D) due to posterior leaflet prolapse, anterior leaflet prolapse, bileaflet prolapse, or chordal rupture—the most surgically repairable etiology

• Patients with severe asymptomatic mitral regurgitation (Stage C) with preserved LVEF (>60%) and LVESD <40mm when repair durability is highly probable (>95%) at a Heart Valve Center of Excellence

• Patients with rheumatic mitral stenosis with favorable valve morphology (Wilkins score ≤8) who are candidates for open mitral commissurotomy or percutaneous mitral balloon commissurotomy (PMBC/Inoue technique)

• Patients with functional or secondary mitral regurgitation in the setting of heart failure (LVEF 20–50%) being considered for transcatheter edge-to-edge repair (TEER) using the MitraClip or PASCAL device when anatomically suitable (COAPT trial criteria: EROA ≥0.2 cm², optimized GDMT)

• Patients with severe tricuspid regurgitation (annular dilation >40mm) undergoing concomitant left-sided valve surgery or isolated high-risk patients considered for transcatheter tricuspid interventions

• Patients with non-calcific, pliable bicuspid aortic valve or isolated aortic regurgitation amenable to aortic valve repair (David reimplantation procedure, Yacoub remodeling procedure)

• Symptomatic patients in NYHA Class II, III, or IV with valvular etiology confirmed by multimodality imaging

• REQUIRED DIAGNOSTIC WORKUP:

• Transthoracic Echocardiography (TTE): First-line assessment of valve morphology, severity grading, ventricular dimensions, LVEF, and pulmonary artery pressures

• Transesophageal Echocardiography (TEE): Mandatory pre-operative and intraoperative tool; 3D TEE provides detailed leaflet segmental analysis (Carpentier classification: Type I, II, III), annular dimensions, and guides intraoperative repair assessment

• Cardiac CT Angiography (CCTA): Annular sizing for transcatheter procedures, aortic root morphology, coronary anatomy, access planning

• Cardiac MRI (CMR): Volumetric quantification of regurgitant fraction and LV remodeling when echocardiographic data is discordant

• Coronary Angiography (invasive): Mandatory in all patients >40 years or with risk factors for CAD to identify concomitant coronary disease requiring CABG

• Right Heart Catheterization: For patients with suspected pulmonary hypertension or discordant hemodynamic data

• 6-Minute Walk Test (6MWT) and Cardiopulmonary Exercise Testing (CPET): Objective functional capacity assessment

• Blood panel: CBC, CMP, coagulation profile (PT/INR, aPTT), HbA1c, lipid panel, thyroid function, BNP/NT-proBNP, blood group and crossmatch

• Chest X-ray, ECG (12-lead), Holter monitoring if paroxysmal atrial fibrillation is suspected

• CONTRAINDICATIONS / COMPLEX CONSIDERATIONS:

• Heavily calcified, immobile, or severely dysplastic valve leaflets where repair is not durable (typically leads to valve replacement decision)

• Active systemic infection or uncontrolled infective endocarditis with active sepsis (surgery delayed until clinical stabilization)

• Severe irreversible LV dysfunction (LVEF <20%) with non-valvular etiology—may not benefit from isolated valve repair

• Prohibitive surgical risk (STS PROM >15%) in patients who may be better served by transcatheter approaches or palliative management

• Uncorrected coagulopathy or severe hepatic failure

• Pregnancy (timing of intervention requires specialized multidisciplinary decision-making)

SURGICAL VALVE REPAIR TECHNIQUES (Open Heart Surgery via Cardiopulmonary Bypass):

1. MITRAL VALVE REPAIR (Gold Standard for Degenerative MR):

• Posterior Leaflet Resection (Quadrangular or Triangular Resection): Carpentier's classic technique for P2 segment prolapse; the prolapsing segment is excised and the annulus is reapproximated with sliding annuloplasty to prevent systolic anterior motion (SAM).

• Artificial Chordoplasty (Neo-chordal Replacement): Expanded PTFE (Gore-Tex) sutures are used to reconstruct ruptured or elongated chordae tendineae; the 'loop technique' and 'chordal transfer' are validated methods with high durability; preferred for anterior leaflet and bileaflet prolapse.

• Annuloplasty Ring Implantation: A rigid, semi-rigid, or flexible annuloplasty ring (e.g., Carpentier-Edwards Physio II, St. Jude Medical Tailor ring, Medtronic Simulus) is sutured to the posterior annulus to remodel the dilated annulus and ensure repair durability; considered mandatory to accompany any leaflet repair to prevent recurrent annular dilation.

• Alfieri Edge-to-Edge Stitch: A suture technique creating a double-orifice valve; now more commonly replicated transcatheterly via TEER devices.

• Cleft Closure, Commissuroplasty: For specific congenital or rheumatic etiologies.

2. AORTIC VALVE REPAIR:

• David Procedure (Valve-Sparing Root Replacement / Reimplantation): The aortic root is replaced with a Dacron graft while the native aortic valve is reimplanted within the graft, preserving the native cusps; preferred for Marfan syndrome, bicuspid aortopathy with cusp prolapse.

• Yacoub Procedure (Remodeling): The three sinuses of Valsalva are replaced without annular stabilization; higher risk of annular re-dilation.

• Cusp Repair Techniques: Plication, triangular resection, pericardial patch augmentation for isolated cusp prolapse or fenestration repair.

3. TRICUSPID VALVE REPAIR:

• DeVega Annuloplasty: Purse-string suture technique for functional tricuspid regurgitation with annular dilation.

• Ring Annuloplasty (Kay, MC3, Contour 3D rings): More durable than suture annuloplasty for significant tricuspid regurgitation.

• Leaflet augmentation with autologous or bovine pericardium for rheumatic or post-endocarditis tricuspid disease.

MINIMALLY INVASIVE SURGICAL APPROACHES:

• Minimally Invasive Mitral Valve Surgery (MIMVS) via Right Mini-Thoracotomy (4–5 cm incision): Avoids full sternotomy; utilizes video-assisted or robotic-assisted visualization; equivalent repair rates to sternotomy with reduced blood loss, shorter ICU stay (1–2 days), faster return to activity (3–4 weeks vs. 6–8 weeks), and superior cosmesis; available at high-volume Indian and UAE centers.

• Robotic-Assisted Mitral Valve Repair (da Vinci Robotic System): Fully endoscopic approach via 4–5 small port incisions (8mm); 3D magnified visualization; tremor filtration and articulated instruments allow precise leaflet and chordal work; outcomes equivalent to open surgery with the fastest recovery profile; offered at select tier-1 cardiac centers in both India and the UAE.

• Port-Access Surgery: Femoral cannulation-based CPB with endoscopic visualization; intermediate between conventional MIMVS and full robotic.

TRANSCATHETER (PERCUTANEOUS) APPROACHES (for High-Surgical-Risk Patients):

• Transcatheter Edge-to-Edge Repair (TEER) — MitraClip (Abbott) / PASCAL (Edwards Lifesciences): Catheter-delivered clip(s) applied to the mitral valve leaflets via transseptal puncture under 3D TEE and fluoroscopic guidance; replicates the Alfieri stitch; FDA-approved for both degenerative MR (EVEREST II trial) and functional MR in HF patients (COAPT trial); ideal for patients with STS PROM >6% or anatomically eligible high-risk patients; performed under general anesthesia; hospital stay 2–3 days.

• Percutaneous Mitral Balloon Commissurotomy (PMBC) / Inoue Balloon Technique: For rheumatic mitral stenosis with favorable morphology (Wilkins ≤8); catheter-based dilation of fused commissures via transseptal approach; avoids open surgery; excellent results in selected patients with restenosis-free survival >80% at 10 years in low-risk anatomy.

• Transcatheter Tricuspid Interventions: Emerging technologies including TRILUMINATE (TriClip), FORMA spacer, CLASP TTr (Edwards); available at select centers.

• TAVR (Transcatheter Aortic Valve Replacement): While primarily a replacement strategy for aortic stenosis, relevant context for patients with combined valvular disease or aortic repair failure.

CONCOMITANT PROCEDURES FREQUENTLY PERFORMED:

• Coronary Artery Bypass Grafting (CABG) combined with valve repair

• Surgical Ablation for Atrial Fibrillation (Cox-Maze IV procedure using bipolar radiofrequency or cryoablation) — restores sinus rhythm in 70–90% of patients

• Left Atrial Appendage Closure (LAAC) for stroke risk reduction in AF patients

PRE-OPERATIVE PHASE (Days –14 to –1):

Step 1 — Remote Consultation & Case Review (2–4 weeks before travel):

Patients share all diagnostic reports (echo reports, cardiac catheterization films, CT/MRI images, ECGs, blood results) with GAF Healthcare's medical coordination team. A senior cardiac surgeon at the selected facility reviews the case and issues a detailed treatment plan including recommended surgical approach (open vs. minimally invasive vs. transcatheter), estimated STS/EuroSCORE II risk, and cost estimate. A video consultation with the operating surgeon is arranged.

Step 2 — Pre-Travel Optimization:

Patients are counseled on pre-operative cardiac optimization: diuretic titration for volume overload, rate or rhythm control for atrial fibrillation, bridging anticoagulation protocols (for patients on warfarin), nutritional assessment, and anemia correction (target Hb >10 g/dL to reduce transfusion risk). Smoking cessation is mandatory ≥4 weeks prior.

Step 3 — Arrival & Admission (Day –2 to –1):

GAF Healthcare arranges airport pickup and transfer to pre-arranged accommodation or hospital guest house. Pre-operative workup is repeated or confirmed in-hospital: TEE, coronary angiography if not recently performed, blood group and crossmatch, anesthesia consultation, chest physiotherapy baseline assessment, consent process with surgical team. Nil-by-mouth instructions and pre-operative skin preparation are initiated.

INTRAOPERATIVE PHASE (Day 0 — Surgery Day):

Step 4 — Surgical Procedure (Duration: 3–6 hours for isolated valve repair; 5–8 hours for complex or combined procedures):

Patient is placed under general anesthesia with continuous invasive hemodynamic monitoring (arterial line, central venous catheter, pulmonary artery catheter in complex cases). Intraoperative 3D Transesophageal Echocardiography (TEE) is performed by a dedicated cardiac anesthesiologist-echocardiographer to re-assess valve anatomy pre-repair and critically evaluate repair adequacy post-repair before separation from cardiopulmonary bypass (CPB).

• For open surgery: Median sternotomy or right mini-thoracotomy incision; cardiopulmonary bypass initiated via aortic and venous cannulation; cold blood cardioplegia (antegrade ± retrograde) arrests the heart; surgeon performs the planned repair under direct visualization with loupe magnification or operating microscope.

• For robotic surgery: Patient positioned with right side elevated; femoral arterial and venous cannulation for CPB; four robotic arms positioned through port incisions; da Vinci system provides surgeon with 3D endoscopic view at 10x magnification.

• On-table TEE assessment post-repair: Confirms <1+ residual regurgitation, absence of systolic anterior motion (SAM), competent repair, and normal biventricular function before CPB is discontinued.

• Defibrillation and cardiac de-airing; CPB weaned; protamine administered to reverse heparin; chest closed with sternal wires (open) or sutures (minimally invasive); chest drain(s) placed.

POST-OPERATIVE PHASE — ICU (Days 1–3):

Step 5 — Cardiac ICU (CICU) Recovery:

Patient is transferred to CICU intubated; extubation typically within 4–8 hours post-operatively for uncomplicated cases (fast-track protocol). Continuous monitoring of cardiac rhythm, arterial blood pressure, central venous pressure, urine output, drainage. Vasopressor/inotrope weaning. Anticoagulation initiated: IV heparin followed by warfarin (target INR 2.0–3.0 for first 3 months post-repair, then aspirin alone if sinus rhythm maintained). Chest physiotherapy commenced from Day 1. Chest drain(s) removed Day 1–2. Epicardial pacing wires removed Day 3–5.

POST-OPERATIVE PHASE — WARD (Days 3–7):

Step 6 — Step-Down Ward & Mobilization:

Patient transferred to cardiac step-down ward. Ambulation progressively increased: sitting Day 2–3, walking short distances Day 3–4, climbing stairs before discharge. Daily wound care; TTE performed on Day 4–5 to confirm repair integrity and rule out pericardial effusion. Oral medications consolidated: ACE inhibitor/ARB, beta-blocker, diuretic, anticoagulation. Cardiac rehabilitation education sessions initiated. Nutritional support optimized.

Step 7 — Discharge Planning (Days 7–12):

Discharge when: hemodynamically stable in sinus rhythm (or rate-controlled AF), wound healing confirmed, oral medications tolerability established, INR therapeutic if on warfarin, TTE confirming adequate repair. Discharge summary, medication list, INR monitoring schedule, and follow-up appointment (clinic review at 4–6 weeks) provided.

POST-DISCHARGE RECOVERY (Weeks 2–6 in Country):

Step 8 — Recovery Accommodation & Outpatient Follow-Up:

GAF Healthcare arranges serviced apartment or hotel accommodation proximate to the hospital. Outpatient clinic review at Week 2: wound check, ECG, INR check (if on warfarin), TTE if indicated. Patients are advised: no driving for 6 weeks (sternotomy patients), no lifting >5 kg for 6–8 weeks, graduated walking program (target 30 minutes/day by Week 4). Sternal precautions maintained for 6–8 weeks (no push-pull activities).

Step 9 — Fit-to-Fly Assessment (Week 4–6):

Formal cardiologist clearance for long-haul flight issued when: sternal wound fully healed, no pericardial effusion, no active arrhythmia requiring in-hospital management, INR stable, patient ambulatory without limitation. Compression stockings and low-molecular-weight heparin (LMWH) are prescribed for the flight in selected high-risk patients (DVT prophylaxis). Emergency medical summary and contact details for home cardiologist provided.

LONG-TERM RECOVERY MILESTONES:

• Return to desk work: 6–8 weeks (open sternotomy); 3–4 weeks (minimally invasive/robotic)

• Return to light physical activity/exercise: 8–12 weeks

• Full physical recovery and return to unrestricted activity: 3–6 months

• Annual surveillance TTE: Lifelong

• Antibiotic prophylaxis for dental procedures: Recommended per AHA/ACC guidelines for repaired valves